Climb Bio Doses First Patients in Budoprutug Phase 2 Trial, Expects Data in H2 2026.

Climb Bio has dosed first patients in its budoprutug Phase 2 trial for pMN, with initial data expected in H2 2026. Dosing is ongoing in budoprutug Phase 1b/2a trials for ITP and Phase 1b trial for SLE, with regulatory clearance for SLE IND in China. The company has also dosed first patients in the CLYM116 Phase 1 healthy volunteer study. Anticipating a data-rich 2026, with initial readouts from all ongoing studies. Climb Bio has a strong financial position with a cash runway expected into 2028.